Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and maintained a $25 price target.
June 21, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Catalyst Pharmaceuticals and maintained a $25 price target.
The reiteration of an Overweight rating and maintenance of a $25 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Catalyst Pharmaceuticals. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100